Levilimab
- Generic Name
- Levilimab
- Drug Type
- Biotech
- CAS Number
- 2035008-70-7
- Unique Ingredient Identifier
- P7UV3L2H80
- Background
Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Biocad
- Target Recruit Count
- 261
- Registration Number
- NCT05800327
- Locations
- 🇷🇺
X7 Clinical Research, Saint Petersburg, Russian Federation
A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Biocad
- Target Recruit Count
- 206
- Registration Number
- NCT04397562
- Locations
- 🇷🇺
Clinical Infectious Disease Hospital named after S.P. Botkin, Saint Petersburg, Russian Federation
🇷🇺Federal State Budgetary Educational Institution of Higher Education "North Ossetian State Medical Academy" of the Ministry of Health of the Russian Federation (FSBEI HE SOGMA of the Ministry of Health of Russia), Vladikavkaz, Russian Federation
🇷🇺State Budget Institution of the Republic of Dagestan "Republican Clinical Hospital", Machačkala, Russian Federation
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.